Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis Therapy
Studies from M. Bastian and co-authors have provided new information about tuberculosis therapy
July 9th, 2008
Data detailed in 'Mycobacterial lipopeptides elicit CD4+ CTLs in Mycobacterium tuberculosis-infected humans' have been presented. According to a study from Ulm, Germany, "In searching for immunogenic molecules with the potential to induce protective immune responses against tuberculosis, we developed an ex vivo model to study frequency, phenotype, and effector functions of human T lymphocytes recognizing hydrophobic Ags of Mycobacterium tuberculosis (M.Tb). To obtain unbiased results, we characterized T lymphocytes responding to a crude cell wall extract (chloroform methanol extract of M.Tb (M.Tb-CME)) containing a broad spectrum of mycobacterial glycolipids and...
Source: Vaccine Weekly (2008-07-09)
|
